+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 80Years
All Genders
ID05643092

Study of Brain Biomarkers and Imaging in Patients with Immune Effector Cell-Associated Neurotoxicity Syndrome Receiving CAR T-Cell Therapy

Led by zhang shoulong · Updated on 2023-03-07

50

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying Immune Effector Cell-Associated Neurotoxicity Syndrome ICANS, a serious complication that can happen with CAR T-cell therapy used to treat blood cancers. The study aims to understand how brain mechanisms change during ICANS by examining brain biomarkers and imaging techniques. The goal is to improve detection and prevention of ICANS by learning more about its effects on the brain. This observational study will measure levels of catecholamines in the cerebrospinal fluid of patients who develop ICANS after receiving CAR T-cell therapy. Participants will also undergo multimodal magnetic resonance imaging MRI to assess brain changes related to ICANS. The research focuses on patients who are scheduled to receive CAR T-cell treatment and tracks brain biomarkers through MRI scans. Participants will be monitored for up to three years following their CAR T-cell infusion. Researchers will track the incidence of CAR-T-associated neurotoxicity and collect data up to one year post-infusion to identify biomarkers and evaluate MRI findings related to ICANS. The study involves regular assessments to better understand the brain changes associated with this neurotoxicity, without administering any additional treatments.

CONDITIONS

Brief Title

Biomarker and Imaging Package Study in Immune Effector Cell-Associated Neurotoxicity Syndrome

Research Team

S

Shoulong Zhang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here